针对癌症相关纤维细胞中的LRRC15修改了细胞外基质,并增强了瘤免疫反应,以抑制肺癌的进展
Lu Qi1, Guohui Dang2, Xinnan Ling1
1Peking University Beijing, Beijing China.
Cancer research
|January 27, 2026
概括
研究人员确定了LRRC15+癌症相关纤维细胞 (CAF) 作为肺癌的标. 抑制LRRC15+CAFs通过重编程巨细胞和促进T细胞来抑制瘤生长,提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 癌症相关纤维细胞 (CAF) 是瘤微环境 (TME) 的关键调节者.
- 由于CAF的异质性,因此需要针对性治疗策略来有效治疗癌症.
- LRRC15+ CAFs代表了TME中的一个独特的子集.
研究的目的:
- 在肺癌中识别和描述瘤特异性的CAF子集.
- 评估LRRC15作为肺癌的潜在治疗标.
- 阐明LRRC15影响TME和抗瘤免疫力的机制.
主要方法:
- 单细胞转录组学用于识别CAF子集.
- 在体内小鼠模型中,评估LRRC15缺乏对瘤进展的影响.
- 流细胞计和分子分析分析巨细胞极化和T细胞激活.
- 开发和测试一种针对LRRC15和TGF-β的双特异性抗体.
主要成果:
- 已确定LRRC15+CAFs是肺癌中的瘤特异性子集.
- LRRC15缺乏通过调节巨细胞极化和增强CD8+ T细胞激活来抑制肺癌的进展.
- 抑制LRRC15降低了细胞外基质的产生,降低了CD206+巨细胞的两极分化,并增加了CD8+ T细胞的细胞毒性.
- 一种针对LRRC15和TGF-β的两种特异性抗体有效地降低了LRRC15的表达,并限制了小鼠的瘤生长.
结论:
- LRRC15是肺癌中一个有前途的治疗点.
- 准LRRC15+CAF可以重新编程TME以增强抗瘤免疫力.
- 这项研究为癌症治疗提供了一种新的CAF导向的治疗策略.
更多相关视频
相关概念视频
01:42The Extracellular Matrix
88.8K
Overview
88.8K
01:29The Extracellular Matrix
12.1K
Overview
In order to maintain tissue organization, many animal cells are surrounded by structural molecules that make up the extracellular matrix (ECM). Together, the molecules in the ECM maintain the structural integrity of tissue as well as the remarkable specific properties of certain tissues.
Composition of the Extracellular Matrix
The extracellular matrix (ECM) is commonly composed of ground substance, a gel-like fluid, fibrous components, and many structurally and functionally diverse...
In order to maintain tissue organization, many animal cells are surrounded by structural molecules that make up the extracellular matrix (ECM). Together, the molecules in the ECM maintain the structural integrity of tissue as well as the remarkable specific properties of certain tissues.
Composition of the Extracellular Matrix
The extracellular matrix (ECM) is commonly composed of ground substance, a gel-like fluid, fibrous components, and many structurally and functionally diverse...
12.1K
01:36Humoral Immune Responses
83.8K
Overview
83.8K
03:03mTOR Signaling and Cancer Progression
4.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.7K
02:57Targeted Cancer Therapies
8.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.9K
02:07Tumor Progression
7.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.4K